Germany’s Pricing Revolution: Why The World Should Be Watching
Executive Summary
Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.
You may also be interested in...
Almirall May Pull Sativex After German Arbitration Board Pricing Decision
Germany’s reimbursement arbitration board has proposed a rock bottom price for GW Pharmaceuticals/Almirall’s cannabinoid preparation Sativex (nabiximols) for MS-related spasticity.
GSK’s Benlysta Discount Isn’t Big Enough To Avoid NICE Rejection
NICE says GSK did not adequately compare its lupus drug belimumab to Roche’s Mab Thera (rituximab). While the firm and partner Human Genome Sciences did offer data that appeared to show an advantage, the problem is that the positive results were more prevalent in a patient population that did not broadly reflect the make-up of the U.K., NICE said.
German Parallel Importers Threaten Action Against Pharma Price Secrecy
Parallel traders of pharmaceuticals in Germany say that hiding the final price of products after negotiations between insurers and manufacturers could destroy their livelihood and is possibly illegal.